# Philippe Szapary

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/philippe-szapary/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,524 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 41 |
| i10-index | 51 |
| Last Known Institution | Cedars-Sinai Medical Center |
| OpenAlex ID | https://openalex.org/A5109165282 |
| Works | 88 |

## Researcher papers

- [A Randomized Trial of a Low-Carbohydrate Diet for Obesity](https://scholariq.org/papers/a-randomized-trial-of-a-low-carbohydrate-diet-for-obesity/)
- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody-2/)
- [Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/ustekinumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up](https://scholariq.org/papers/long-term-safety-of-ustekinumab-in-patients-with-moderate-to-severe-psoriasis/)
- [Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis](https://scholariq.org/papers/guselkumab-an-il-23-specific-mab-demonstrates-clinical-and-molecular-response-in/)
- [A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis](https://scholariq.org/papers/a-phase-2-trial-of-guselkumab-versus-adalimumab-for-plaque-psoriasis/)
- [Flaxseed and Cardiovascular Risk Factors: Results from a Double Blind, Randomized, Controlled Clinical Trial](https://scholariq.org/papers/flaxseed-and-cardiovascular-risk-factors-results-from-a-double-blind-randomized/)
- [Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease](https://scholariq.org/papers/pharmacokinetics-and-exposure-response-relationships-of-ustekinumab-in-patients/)
- [Guggulipid for the Treatment of Hypercholesterolemia](https://scholariq.org/papers/guggulipid-for-the-treatment-of-hypercholesterolemia/)
- [Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study](https://scholariq.org/papers/ustekinumab-in-adolescent-patients-age-12-to-17-years-with-moderate-to-severe/)
- [A randomized trial of the effects of an almond-enriched, hypocaloric diet in the treatment of obesity](https://scholariq.org/papers/a-randomized-trial-of-the-effects-of-an-almond-enriched-hypocaloric-diet-in-the/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)

## Researcher university

- [Cedars-Sinai Medical Center](https://scholariq.org/institutions/cedars-sinai-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.